Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ortho-McNeil Levaquin

Executive Summary

The anti-infectives committee will review levofloxacin for the treatment of community acquired pneumonia due to penicillin-resistant S. pneumonia on the afternoon of Oct. 20. The committee will consider development of antimicrobial drugs for the treatment of catheter-related blood stream infections in the morning session, beginning at 9 a.m

You may also be interested in...

J&J Levaquin Review Could Affect Bristol's Positioning Of Tequin

The upcoming advisory committee review of a new indication for Ortho McNeil's Levaquin (levofloxacin) could affect Bristol-Myers Squibb's positioning of its pending quinolone antibiotic Tequin (gatifloxacin).

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts